Routine annual meeting results filing with no immediate trading catalyst. Monitor future equity grant activity under the expanded plan for potential dilution, but no action warranted based on this filing alone.
Price Chart
Executive Summary
Esperion Therapeutics filed an 8-K reporting the results of its 2026 annual meeting of stockholders held on May 28, 2026. Stockholders approved all four proposals, including the re-election of two Class I directors (J. Martin Carroll and Sheldon L. Koenig), a non-binding advisory vote on executive compensation, ratification of Ernst & Young as independent auditor, and a Fourth Amendment to the 2022 Stock Option and Incentive Plan increasing authorized shares by 7,000,000 to a total of 30,150,000 shares. This is a routine post-meeting filing with no material financial impact.
Key Facts
- Annual meeting held May 28, 2026; all four stockholder proposals approved.
- Class I directors J. Martin Carroll and Sheldon L. Koenig re-elected.
- Fourth Amendment to 2022 Stock Option and Incentive Plan approved, increasing authorized shares by 7,000,000 to 30,150,000 total.
- 257,404,876 shares of common stock outstanding as of March 31, 2026 record date.
- Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2026.
Financial Impact
No financial figures reported. The 7,000,000 share increase to the equity incentive plan is a routine authorization; no actual issuance or dilution occurred with this filing.
Risk Factors
- Potential future dilution from equity awards under the expanded 2022 Plan, though no grants are disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-039518 |
| Document: espr-20260528.htm | 0001628280-26-039518 |
| Document: 0001628280-26-039518-index-headers.html | 0001628280-26-039518 |
| Document: 0001628280-26-039518-index.html | 0001628280-26-039518 |
| Document: 0001628280-26-039518.txt | 0001628280-26-039518 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | — | awaiting T+5 | — | — |
Aug 13, 2026 7w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 23, 2026 10w ago | 15-12G | — | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | — | — |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | ▼ −0.63% | ▲ +0.41% | — |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | ▲ +0.63% | ▲ +0.20% | — |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | ▲ +0.64% | ▼ −2.80% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access